Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13209294 | 0.85 | FYN (0.50) | SCDMAPTSMARCA2SMARCA4MAPK1 | |
| SCHEMBL13209278 | 0.83 | FYN (0.42) | SCDMAPTSMARCA2SMARCA4MAPK1 | |
| SCHEMBL30238422 | 0.81 | STING1 (0.50) | SMARCA2SMARCA4MAPK1STING1EP300 | |
| SCHEMBL4517082 | 0.78 | SMARCA2 (0.48) | SCDMAPTSMARCA2SMARCA4MAPK1 | |
| SCHEMBL24921987 | 0.77 | MAPT (0.50) | SCDMAPTSMARCA2SMARCA4MAPK1 | |
| SCHEMBL13209251 | 0.76 | MAPT (0.46) | SCDMAPTSMARCA2SMARCA4MAPK1 | |
| SCHEMBL22971335 | 0.76 | JAK2 (0.48) | SCDMAPTMAPK1STING1FYN | |
| SCHEMBL14784060 | 0.75 | GPR55 (0.56) | MAPTFYNEP300 | |
| SCHEMBL29520095 | 0.75 | FGFR3 (0.47) | SCDMAPTSMARCA2SMARCA4MAPK1 | |
| SCHEMBL19370344 | 0.75 | STING1 (0.43) | SCDMAPTSMARCA2SMARCA4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108864101-B | Deuterated SGX523 and application thereof | 中国科学院上海药物研究所 | 2019-12-17 | — | — | CN | disclosed |
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180244695-A1 | QUINOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2018-08-30 | — | — | US | disclosed |
| EP-2598144-B1 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | LILLY CO ELI (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2598144-B1 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | LILLY CO ELI (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2598144-A1 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | Eli Lilly and Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015677-A9 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | ELI LILLY AND COMPANY (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012015677-A9 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | ELI LILLY AND COMPANY (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2081937-A2 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244695-A1 | QUINOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | MET, ABL1, KRAS | SCD 3822/4885MAPT 3447/4885SMARCA2 4372/4885 |
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | MET, ABL1, KRAS | SCD 3822/4885MAPT 3447/4885SMARCA2 4372/4885 |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | MAP4K5, MAPKAPK5, MAP4K2 | SCD 3261/4885MAPT 3032/4885SMARCA2 4253/4885 |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | SCD 3347/4885MAPT 1886/4885SMARCA2 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.